2026 AAFP FMX - From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care

HAZLET, N.J. - Rezul -- Three experts in the management of T2D and cardiovascular risk will guide attendees through the evidence, guidelines, and exam room conversations and prescribing decisions that will improve the outcomes for their patients.

Click here for more information

CHAIR
Jay Shubrook, DO, FACOFP, FAAFP
Professor & Diabetologist
Department of Clinical Sciences &
Community Health
Diabetes Institute
Touro University California College of
Osteopathic Medicine
Vallejo, California

FACULTY
Silvio Inzucchi, MD
Clinical Chief of the Section of Endocrinology
Professor of Medicine
Yale University School of Medicine
New Haven, Connecticut

Lawrence A. Leiter, MD, FRCPC
Division of Endocrinology & Metabolism
St. Michael's Hospital
Professor of Medicine & Nutritional Sciences
University of Toronto
Toronto, Canada

More on Rezul News

• Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
• OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
• P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
• DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
• Rural California Energy Consultancy Unlocks Remote Sites for Vacation Rentals and ADUs

Educational Objectives
■ Apply the 2026 ADA Standards of Care guideline recommendations to
identify primary care patients with T2D who are candidates for GLP-1
RA therapy, including those with established ASCVD, CKD, or multiple
cardiovascular risk factors
■ Interpret the cardiovascular outcomes trial evidence with GLP-1 RA therapy
and translate key findings into clinical decisions for primary care patients
with T2D
■ Initiate oral or injectable GLP-1 RA therapy in appropriate primary care
patients with T2D, including patients who are injection-averse, using
correct dosing, titration, and administration guidance
■ Counsel primary care patients with T2D on the benefits, tolerability,
administration requirements, and class safety profile of GLP-1 RA therapy
to support shared decision-making and long-term adherence

Target Audience
This program is intended for primary care clinicians and other healthcare
professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from

More on Rezul News

• Apple Valley Home Sales Rise 22.0% as Active Listings Fall 20.2%
• French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
• LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
• 303 Crown Maids Enhances Commercial Cleaning Services Page for Local Businesses
• GreenPointe Holdings promotes Megan Maldonado to Senior Developed Real Estate Manager

Novo Nordisk Inc.

Accreditation and Credit Designation Statements
This live activity, From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care, with a beginning date of 10/23/26, has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.